# Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/42866
Published: 2026-10-28T19:23:49.000Z
Updated: 2026-10-28T19:23:49.000Z
Section: Business

> The Phase 3 data involved certain patients with head and neck cancer. Petosemtamab is a bispecific antibody therapy.

Genmab A/S said Oct. 28 that petosemtamab combined with Merck’s Keytruda (pembrolizumab) cut mortality risk by 50% in Phase 3 data involving certain patients with head and neck cancer.

Petosemtamab is a bispecific antibody therapy.